Tilray Brands (TLRY) Aktievy
Tilray Brands, Inc. är ett företag inom livsstilsprodukter för konsumenter som bedriver forskning, odling, bearbetning och distribution av medicinska cannabisprodukter i Kanada, USA, Europa, Mellanöstern, Afrika och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
TLRY Community Fair Values
Create NarrativeSee what 171 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Tilray Brands, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$4.67 |
| 52 veckors högsta | US$23.20 |
| 52 veckors lägsta | US$3.67 |
| Beta | 1.92 |
| 1 månads förändring | 8.60% |
| 3 månaders förändring | -9.85% |
| 1 års förändring | -54.66% |
| 3 års förändring | -82.31% |
| 5 års förändring | -96.36% |
| Förändring sedan börsintroduktionen | -97.10% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 12
TLRY: New Beverage And Medical Expansion Will Drive Future Upside Potential
Analysts have trimmed their average price target on Tilray Brands. Recent estimates have moved from around $10.04 to about $7.84, citing lower modeled revenue growth, a slightly higher discount rate, and updates to sales expectations, including a cut to a $5 target from $7, along with more cautious views on international cannabis permits and beverage demand.
Uppdatering av berättelse • Jul 29
TLRY: Beverage And Medical Expansion Will Drive Long Term Cash Flow
Analysts have reduced their fair value estimate for Tilray Brands, cutting the price target by about $3 after revising assumptions for revenue growth, profit margins and future P/E in light of more cautious expectations for international cannabis permits and beverage sales. What's in the News for Tilray Brands Tilray Medical launched its first medical cannabis product in Panama, Tilray Oral Solution CBD100, manufactured at its EU-GMP certified facility in Portugal and distributed through Farmacias Arrocha under medical prescription.Seeking Alpha • Jul 29
Tilray Q4: Dilution Outweighs Progress
Summary Tilray Brands delivered strong Q4 revenue growth, driven by the BrewDog acquisition, but shares hit new lows due to ongoing dilution. Despite revenue gains, most segment gross margins stagnated, and adjusted net income fell 60% year over year, highlighting persistent profitability challenges. The company's valuation remains quite depressed compared to peer Canopy Growth, which is expected to show more revenue growth. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Aug 12
TLRY: New Beverage And Medical Expansion Will Drive Future Upside Potential
Analysts have trimmed their average price target on Tilray Brands. Recent estimates have moved from around $10.04 to about $7.84, citing lower modeled revenue growth, a slightly higher discount rate, and updates to sales expectations, including a cut to a $5 target from $7, along with more cautious views on international cannabis permits and beverage demand.Uppdatering av berättelse • Jul 29
TLRY: Beverage And Medical Expansion Will Drive Long Term Cash Flow
Analysts have reduced their fair value estimate for Tilray Brands, cutting the price target by about $3 after revising assumptions for revenue growth, profit margins and future P/E in light of more cautious expectations for international cannabis permits and beverage sales. What's in the News for Tilray Brands Tilray Medical launched its first medical cannabis product in Panama, Tilray Oral Solution CBD100, manufactured at its EU-GMP certified facility in Portugal and distributed through Farmacias Arrocha under medical prescription.Seeking Alpha • Jul 29
Tilray Q4: Dilution Outweighs Progress
Summary Tilray Brands delivered strong Q4 revenue growth, driven by the BrewDog acquisition, but shares hit new lows due to ongoing dilution. Despite revenue gains, most segment gross margins stagnated, and adjusted net income fell 60% year over year, highlighting persistent profitability challenges. The company's valuation remains quite depressed compared to peer Canopy Growth, which is expected to show more revenue growth. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jul 14
TLRY: Partial Rescheduling And Medical Assets Will Support Future Cash Flow Visibility
Analysts have trimmed their 12 month price target for Tilray Brands to $5.00 from $6.50, citing updated expectations for slower revenue growth, slightly lower profit margins, and a reduced future P/E multiple following recent adjustments to sales forecasts and cannabis permit timing. Analyst Commentary Recent research updates on Tilray Brands highlight a more cautious tone, with several bearish analysts revisiting their revenue assumptions, margin outlook, and valuation frameworks in light of revised sales expectations and cannabis permit timing.Uppdatering av berättelse • Jun 24
TLRY: Partial Cannabis Rescheduling And Beverage Partnerships Will Improve Future Cash Flow Visibility
Analysts recently trimmed their average 12 month price target for Tilray Brands to about $6.50 from roughly $9.00. This reflects updated assumptions for slower revenue growth, slightly lower profit margins, a higher discount rate and a reduced future P/E multiple, even as some research cites potential benefits from partial cannabis re scheduling.Uppdatering av berättelse • Jun 06
TLRY: Cannabis Rescheduling And Margin Outlook Will Drive Future Upside Potential
Tilray Brands' consensus analyst price target has been reset lower by roughly $2 to $3 per share as analysts factor in updated cannabis re-scheduling expectations and revised profit margin and future P/E assumptions following recent firm-level target cuts and one upgrade. Analyst Commentary Recent Street research on Tilray Brands shows a mix of optimism around potential regulatory shifts and caution around profit expectations and valuation multiples.Uppdatering av berättelse • May 17
TLRY: BrewDog Deal And Cannabis Rescheduling Will Shape Future Upside Potential
Analysts have trimmed their average price target on Tilray Brands by a few dollars to reflect updated assumptions around discount rates, profit margins and future P/E multiples, even as some highlight potential benefits from partial cannabis rescheduling and recent acquisitions. Analyst Commentary Bullish Takeaways Bullish analysts view the partial cannabis rescheduling order as extremely favorable, seeing scope for improved sector sentiment and potential support for valuation multiples if regulatory risk is perceived as lower.Uppdatering av berättelse • May 02
TLRY: BrewDog Acquisition And Cannabis Rescheduling Will Drive Future Upside
Analysts have cut their average price target on Tilray Brands to about $10.04 from $16.17, reflecting updated assumptions on discount rates, revenue growth, profit margins, and a reset future P/E following recent research that includes target reductions tied to the BrewDog asset acquisition and evolving views on potential U.S. cannabis rescheduling. Analyst Commentary Recent research on Tilray Brands highlights a mix of optimism around regulatory developments and caution around execution risks, especially following the BrewDog asset acquisition and a series of price target resets.Uppdatering av berättelse • Apr 18
TLRY: BrewDog Integration And Synergies Will Support Long Term Cash Flow Potential
The analyst price target for Tilray Brands has been reduced by several dollars to $9.00. This reflects analysts' focus on lower future P/E assumptions and execution risks around recent acquisitions, even as they factor in slightly higher revenue growth and profit margin estimates.Uppdatering av berättelse • Apr 04
TLRY: BrewDog Acquisition Execution Will Support Long Term Cash Flow Visibility
Tilray Brands' updated analyst price target framework now points to an implied fair value shift from $19.22 to $20.25. Analysts cite changes to revenue growth assumptions, profit margin expectations, and a higher future P/E multiple following a mix of price target cuts and a recent upgrade on the stock.Uppdatering av berättelse • Mar 20
TLRY: BrewDog Acquisition Synergies And Schedule III Shift Will Improve Cash Flow Visibility
Analysts have reduced their Tilray Brands price targets to $9.00 from $10.00, reflecting caution regarding the BrewDog asset acquisition and a focus on the company demonstrating it can achieve operational synergies, as well as provide clearer long term visibility into sales and cash flows. Analyst Commentary Recent research updates point to a cautious stance on Tilray Brands, with several Bearish analysts trimming price targets and reiterating more neutral views after both the BrewDog asset acquisition and the latest quarterly results.Uppdatering av berättelse • Mar 05
TLRY: Schedule III Shift And Medical Push Will Improve Cash Flow Visibility
Narrative Update on Tilray Brands The analyst price target for Tilray Brands has been trimmed from $9.25 to $9.00 as analysts factor in a slightly higher discount rate, a lower assumed future P/E, and execution risks and synergy uncertainty around the BrewDog asset acquisition, even though revenue growth and profit margin assumptions remain modestly higher. Analyst Commentary Recent Street research on Tilray Brands has leaned cautious, with multiple bearish analysts trimming price targets and maintaining neutral stances despite some operational positives.Uppdatering av berättelse • Feb 19
TLRY: Rescheduling And Licensing Agreements Will Support Long Term Cash Flow Visibility
Analysts have updated their price target on Tilray Brands to $19.22 from $1.83, reflecting revised assumptions around revenue growth, profit margins, and future P/E following recent coverage initiations and target resets that cited solid Q2 sales with mixed visibility on long-term sales and cash flow. Analyst Commentary Recent Street commentary around Tilray Brands has been mixed, with some firms trimming price targets while keeping ratings neutral.Uppdatering av berättelse • Feb 05
TLRY: Schedule III Rescheduling And Medical Expansion Will Support Cash Flow Visibility
Analysts have trimmed their price targets on Tilray Brands to around $10, reflecting a more cautious stance after recent quarterly results that they viewed as generally in line. Solid international and distribution sales were partly offset by ongoing questions around long term sales visibility and cash flow.Uppdatering av berättelse • Jan 21
TLRY: Schedule III Shift Will Test Medical Expansion And Cash Flow Visibility
Analysts have adjusted their fair value estimate for Tilray Brands from $8.50 to $9.25, citing recent target revisions that reflect more cautious revenue growth assumptions, steady profitability expectations, and an updated outlook for the future price-to-earnings ratio. Analyst Commentary Recent Street research has leaned cautious on Tilray Brands, with bearish analysts trimming price targets and flagging risks around visibility into the company’s longer term financial profile.Analysartikel • Jan 16
Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 30% Price Drop
To the annoyance of some shareholders, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares are down a considerable 30% in the...Uppdatering av berättelse • Jan 06
TLRY: Rescheduling To Schedule III Will Expose Medical Expansion Hurdles
Analysts have lifted their fair value estimate for Tilray Brands to $8.50 from $0.60, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they see as better reflecting the company’s current risk and earnings profile. What's in the News President Trump signed an executive order directing Attorney General Pam Bondi to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act.Uppdatering av berättelse • Dec 20
TLRY: Reverse Split Will Drive Future Upside As Medical Expansion Advances
Analysts have modestly raised their price target on Tilray Brands to reflect slightly stronger long term revenue growth expectations, even as they factor in significantly compressed profit margins and a sharply higher assumed future price to earnings multiple. What's in the News Tilray Medical outlined a strategic framework for U.S. medical cannabis expansion following federal rescheduling, creating Tilray Medical USA Inc.Uppdatering av berättelse • Dec 06
TLRY: Reverse Split And Medical Expansion Will Drive Future Upside
Analysts have significantly raised their price target on Tilray Brands, lifting fair value expectations from approximately $1.78 to $16.17 per share, citing improved long term earnings visibility and a more favorable valuation multiple outlook. What's in the News Announced a 1 for 10 reverse stock split effective December 2, 2025, aiming to support continued Nasdaq listing and broaden institutional investor eligibility (company announcement).Analysartikel • Nov 24
Tilray Brands, Inc. (NASDAQ:TLRY) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough
The Tilray Brands, Inc. ( NASDAQ:TLRY ) share price has fared very poorly over the last month, falling by a substantial...Uppdatering av berättelse • Nov 22
TLRY: Federal Policy Shifts Will Drive New U.S. Cannabis Opportunities
Analysts have raised Tilray Brands' price target from $1.50 to $2.00, citing strengthened expectations due to shifting U.S. federal policy toward cannabis and the company's strong market position. Analyst Commentary Analysts have highlighted a range of factors that support an optimistic outlook for Tilray Brands, while also noting certain risks that could affect the company's future performance.Uppdatering av berättelse • Nov 07
TLRY: Progress On U.S. Rescheduling Will Unlock New Market Access
Tilray Brands has received an increased analyst price target from $1.50 to $2.00 per share, reflecting greater optimism because of anticipated regulatory changes and the company’s strong industry positioning. Analyst Commentary Bullish analysts have reacted positively to recent developments affecting Tilray Brands, noting a number of factors that could drive further growth and improve the company’s outlook.Uppdatering av berättelse • Oct 23
Upcoming Federal Policy Shifts Will Open New Opportunities In Cannabis Markets
Analysts have raised their price target on Tilray Brands from $1.50 to $2.00, citing recent shifts in U.S. federal policy toward cannabis and the company's strong positioning to benefit from potential market expansion. Analyst Commentary Following the price target increase, analysts have shared both optimistic and cautious perspectives on Tilray Brands, reflecting on the company's future prospects and potential risks.Uppdatering av berättelse • Oct 09
Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Analysts have raised their price target for Tilray Brands from $1.50 to $2.00, citing anticipated progress in U.S. cannabis policy and Tilray's strong positioning to benefit from broader market access. Analyst Commentary Recent commentary from bullish analysts highlights both the strengths and potential hurdles facing Tilray Brands in the evolving cannabis market.Analysartikel • Oct 03
Tilray Brands, Inc.'s (NASDAQ:TLRY) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have continued their recent momentum with a 29% gain in the last month...Uppdatering av berättelse • Aug 26
Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Tilray Brands’ consensus price target has increased to $0.983 as analysts cite improved U.S. political momentum toward cannabis rescheduling and Tilray’s strong positioning to benefit from expanding market opportunities. Analyst Commentary Positive political developments, with momentum towards rescheduling marijuana from Schedule I to Schedule III in the U.S., indicating a potential shift in federal cannabis policy.Analysartikel • Aug 18
Tilray Brands, Inc. (NASDAQ:TLRY) Surges 66% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have been powering on, with a gain of 66% in...Analysartikel • Jul 04
Tilray Brands, Inc. (NASDAQ:TLRY) Shares Fly 35% But Investors Aren't Buying For Growth
Tilray Brands, Inc. ( NASDAQ:TLRY ) shareholders are no doubt pleased to see that the share price has bounced 35% in...Aktieägarnas avkastning
| TLRY | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | 2.2% | 0.6% | 0.6% |
| 1Y | -54.7% | 49.9% | 20.1% |
Avkastning vs industri: TLRY presterade sämre än US Pharmaceuticals branschen som gav 49.9 % under det senaste året.
Avkastning vs Marknaden: TLRY presterade sämre än US marknaden som gav 20.1 % under det senaste året.
Prisvolatilitet
| TLRY volatility | |
|---|---|
| TLRY Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: TLRY har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: TLRY s veckovolatilitet har minskat från 16% till 6% under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| n/a | 3,595 | Irwin Simon | www.tilray.com |
Tilray Brands, Inc., ett företag inom livsstils- och konsumentprodukter, bedriver forskning, odling, bearbetning och distribution av medicinska cannabisprodukter i Kanada, USA, Europa, Mellanöstern, Afrika och på internationell nivå. Företaget bedriver sin verksamhet inom fyra segment: Drycker, Cannabis, Distribution och Hälsa. Det erbjuder även medicinska cannabisprodukter och cannabisprodukter för vuxna; återförsäljer och distribuerar läkemedel och hälsoprodukter; samt producerar, marknadsför och säljer dryckesprodukter och hampabaserade livsmedelsprodukter.
Tilray Brands, Inc. Sammanfattning av grunderna
| TLRY grundläggande statistik | |
|---|---|
| Börsvärde | US$633.32m |
| Vinst(TTM) | -US$121.40m |
| Intäkter(TTM) | US$915.45m |
0.7x
P/S-förhållande-5.2x
P/E-förhållandeÄr TLRY övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| TLRY resultaträkning (TTM) | |
|---|---|
| Intäkter | US$915.45m |
| Kostnad för intäkter | US$652.86m |
| Bruttovinst | US$262.59m |
| Övriga kostnader | US$383.99m |
| Intäkter | -US$121.40m |
Senast redovisade vinst
May 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.90 |
| Bruttomarginal | 28.68% |
| Nettovinstmarginal | -13.26% |
| Skuld/egenkapitalförhållande | 14.2% |
Hur har TLRY utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/16 02:24 |
| Aktiekurs vid dagens slut | 2026/08/14 00:00 |
| Intäkter | 2026/05/31 |
| Årlig intjäning | 2026/05/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Tilray Brands, Inc. bevakas av 27 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |